09.12.2009 • Topics

Sanofi Spending €350 Million on Vaccine Site

France's Sanofi-Aventis is spending €350 million to build a site to produce a potential blockbuster dengue vaccine that is still in development. The high-technology site should be up and running in 2013 to produce 100 million doses of the dengue vaccine which should become available in 2014 in the endemic regions such as Asia Pacific. The new plant will be located in Neuville-sur-Saone, near Sanofi Pasteur's headquarters in Lyon, France. Sanofi has 12 manufacturing sites under construction or undergoing major renovation and they will come on line in 2009. Among them is the recently approved U.S. factory in Pennsylvania, which is to produce the seasonal flu vaccine Fluzone.

Special Issue

Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.